A new JCEM review listing puts testosterone trial evidence in context, with separate findings on sexual benefits, cardiovascular events and metabolic outcomes.
The Journal of Clinical Endocrinology & Metabolism listed a mini-review by Milena Braga and Shehzad Basaria published September 26, 2026. Titled “Key findings on the efficacy and safety of testosterone therapy from two large randomized trials,” it appears as article dgag397.
This article is for informational purposes and is not medical advice. Individual decisions about testosterone therapy belong with a qualified clinician.
For clinical background, the European Association of Urology (EAU) male-hypogonadism guideline provides summaries of TRAVERSE and T4DM. These guideline findings offer context for the subject of the publication notice.
The distinction between outcomes matters. Improvement in sexual desire is not the same result as improvement in erectile function. Likewise, a finding about major cardiovascular events answers a different question from a finding about prostate cancer or diabetes.
Reading these results separately gives a more useful account of testosterone replacement therapy, or TRT, than a single statement that treatment “works” or is “safe.”
The EAU guideline describes TRAVERSE as a non-inferiority trial of testosterone gel in middle-aged and older men with hypogonadism. Participants also had existing cardiovascular disease or high cardiovascular risk.
According to the guideline, treatment improved sexual activity and sexual desire. It also improved hypogonadal symptoms. The guideline reports no improvement in erectile function.
These are distinct findings rather than contradictory ones. A result about desire should be described as a result about desire. Expanding it into a claim about every aspect of sexual function would change what the study reported.
For a reader considering treatment expectations, the useful question is which specific outcome improved. “Sexual benefit” is too broad if it leaves the impression that desire and erections responded in the same way. Testostra's discussion of the distinction between desire and erections addresses this important difference in terminology.
The EAU guideline reports that TRAVERSE met its non-inferiority criterion for major adverse cardiovascular events. This is the trial's reported finding for that outcome.
The guideline also reports that atrial fibrillation and acute kidney injury occurred more often in the testosterone group. Pulmonary embolism was observed more often as well.
Both parts belong in an accurate account. Reporting only the major cardiovascular event result would leave out the adverse-event differences. Reporting only those differences would leave out the trial's non-inferiority finding.
The guideline's broader assessment says that several interventional studies it reviewed did not show increased major adverse cardiovascular events. It nevertheless includes the other TRAVERSE findings rather than treating that major-event result as a complete safety verdict.
This is why the endpoint deserves as much attention as the headline. A statement about one category of events should remain attached to that category. Understanding how trial design shapes safety claims helps keep the interpretation tied to the actual research question.
In its prostate-safety discussion, the EAU guideline reports no between-group difference in prostate-cancer incidence in TRAVERSE over a mean follow-up of 33 months. It also reports no difference in high-grade prostate-cancer rates during that period.
At the same time, total PSA rose more from baseline in the testosterone group.
The cancer findings and the PSA finding should remain separate in the summary. A comparison of cancer incidence is not interchangeable with a comparison of changes in a laboratory marker. The guideline reports both.
For readers, this means that a headline about prostate cancer should not silently become a claim that testosterone has no prostate-related effects. A useful account of prostate outcomes in treatment research needs to preserve the distinction between the outcomes being measured.
The EAU guideline describes T4DM as a two-year, placebo-controlled trial involving 1,007 men. Participants had impaired glucose tolerance or newly diagnosed type 2 diabetes and testosterone below 14 nmol/L.
According to the guideline, a lower proportion of men receiving testosterone met the trial's diabetes criterion. It reports this finding regardless of lifestyle-program participation.
The precise wording is important. The reported result concerns the proportion meeting a defined trial criterion. It should not be rewritten as a general promise that testosterone prevents diabetes.
The testosterone value also belongs to the description of this study's participants. It should remain attached to that description rather than being presented as a stand-alone treatment rule.
For an evidence summary, the useful sequence is to identify the population and the outcome before discussing the result. That preserves the metabolic finding without turning it into a recommendation for routine diabetes prevention.
A 2026 systematic review and meta-analysis published in Endocrine included 31 randomized controlled trials and 9,437 participants. Treatment durations ranged from 40 days to 36 months.
The analysis reported a possible arrhythmia signal. Its authors said the clinical significance remained uncertain.
This is a separate piece of cardiovascular evidence alongside the guideline's account of TRAVERSE. It adds a question about arrhythmias to the discussion rather than replacing the major cardiovascular event finding.
The authors' uncertainty is part of the result and should be retained when it is reported. Neither a definite causal claim nor a dismissal of the signal would reflect the approved finding.
The JCEM advance listing establishes the mini-review's title and authors. It also establishes its publication date and article type. It does not identify the trials discussed or set out the authors' detailed interpretation and practical conclusions.
The EAU summaries therefore remain background evidence. They are not confirmation that TRAVERSE and T4DM are the trials covered by Braga and Basaria. Establishing the mini-review's own conclusions requires checking its full text and citations.
Population also sets the scope of the findings. The cardiovascular-risk population in TRAVERSE and the glucose-selected population in T4DM should not be merged into a single category of all adult men. Their results need clinical interpretation before being applied to a different patient profile.
Treatment and observation periods impose another boundary. The prostate findings describe the reported follow-up rather than every future year of treatment. The meta-analysis also combines studies with differing treatment durations. These observations do not provide an unlimited-duration safety conclusion.
Finally, TRAVERSE evaluated testosterone gel. Transferring its findings automatically to every testosterone product or use pattern would go beyond the trial description available here.
The practical reading rule is straightforward: keep each finding attached to its population and outcome. Keep its treatment context and observation period visible as well. That approach preserves useful evidence without asking it to answer a broader question than the research addressed.
The bottom line is continuity rather than a change in medical practice. The available publication notice does not support starting testosterone therapy or changing an existing prescription. It also does not supply a new clinical recommendation for diabetes prevention or a blanket assurance about treatment safety.
The guideline context remains useful for a different purpose: setting accurate expectations. Its summaries distinguish sexual desire from erectile function. They also separate major cardiovascular events from other adverse events and prostate-cancer outcomes from PSA changes.
For a clinical conversation, the most useful questions follow those distinctions:
These questions help organize a discussion without turning a research brief into an individual treatment plan. A qualified clinician is the appropriate person to connect the evidence with a man's symptoms and health history.
The September publication is a reason to examine the review when its full contents can be assessed. For current care, the responsible conclusion is narrower: evaluate benefits and harms by endpoint rather than treating “efficacy and safety” as a single verdict.
Turning a trial headline into a blanket safety claim is the mistake Testostra's evidence-led reporting is designed to avoid. For men faced with marketing or social-media claims about TRT, the publication explains research uncertainty and clinical boundaries in readable language, supporting informed questions rather than a decision based on an oversimplified headline.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra